Sernova Says FDA Grants Orphan Drug Designation For Autologous Islet Transplantationrttnews·Jun 17 at 07:19 AMSEOVF+4.88%
Keenova Reports First Quarter 2026 Financial Results | MNK Stock NewsStockTitan·May 11 at 09:30 PMSEOVF+4.88%ITRM0.00%
Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking | MNK Stock NewsStockTitan·May 3 at 10:30 PMNBRVF0.00%ITRM0.00%
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week | MNK Stock NewsStockTitan·Apr 30 at 10:30 PMITRM0.00%NBRVF0.00%
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders | SEOVF Stock NewsStockTitan·Apr 8 at 10:00 PMIXJ-1.43%VHT-1.65%
06:30 ETKeenova Announces Unaudited Fourth Quarter 2025 Financial Resultsprnewswire·Mar 31 at 05:30 AMLABU+2.56%BBH-1.55%
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge | MNK Stock NewsStockTitan·Mar 26 at 10:30 PMRNVA0.00%SEOVF+4.88%
Sernova Raises $2.1 Million in Private Placement to Advance Diabetes ProgramTip Ranks·Mar 24 at 11:40 AMVHT-1.65%SVA0.00%
Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above.benzinga_article·Mar 23 at 09:56 AMIBBQ-0.46%XBI+0.82%
